Oncology and Carcinogenesis articles for Germany

Time frame: 1 July 2025 - 30 June 2026

View topic

Count: 482

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
2 0.16
Metallosalphen-Covalent Organic Framework-Based Semiconducting Artificial Enzymes with Radio-Activable Antitumor Immunity for Suppressing Tumor Metastasis and Recurrence 0.12
Peroxidase-Inspired Polyphthalocyanine Networks with Highly Efficient Sonocatalytic Activities for On-Demand Tumor Immunotherapies in Breast Cancers 0.04
2 0.08
Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity 0.06
Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells 0.02
3 1.36
Global Cold Local Photothermal‐Mediated Synergistic Metabolic Antitumor Immunity 0.10
Light Activated Induction of Cuproptosis in Resistant Cancer Cells Using Polymeric BODIPY Nanoparticles for Photoactivated Chemotherapy 1.00
Immune-Engineered Hydrogels Combat Orthotopic and Metastatic Cancer via Hypoxia-Relieved Photodynamic Therapy and Ferroptotic Cell Death 0.26
1 0.14
NIR-II Photoactivatable Cobalt(III) Nanoparticles for Photoactivated Metal Chemo-Immunotherapy 0.14
1 0.16
Obesity promotes conserved inflammatory and metabolic transcriptional programs in colon tumors: Evidence from mouse models and the ColoCare Study patient cohort 0.16
2 0.20
Bi-allelic variants in neuronal adhesion molecule astrotactin 1 gene ASTN1 cause diverse neurodevelopmental disorders 0.10
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes 0.10
2 1.56
Unlocking SLC6A15 (B0AT2): A Dual-Platform Approach To Accelerate Drug Discovery for Neuropsychiatric Disorders 1.00
Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast Cancer 0.56
5 2.95
Boosting Cancer Chemoimmunotherapy with Mitochondria-Targeting Iridium(III)-Based Immunogenic Oncosis Inducers 0.13
Conditional Stabilization of the Hypoxia‐Inducible Factor HIF1α— Photoswitchable Stapled Peptides Prevent Elongin BC–Mediated Degradation 1.00
Cyclometalating Ligand Affords NIR Absorption in Ruthenium Complexes for Type‐I Photodynamic Therapy 0.07
Interactome Profiling of a Lysine Deacetylase Trapping Probe Library Uncovers Crosstalk Between HDAC6 and NF‐κB Signaling 1.00
Redirecting the Peptide Cleavage Causes Protease Inactivation 0.76
1 0.06
Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up. 0.06
1 0.75
Recombinant Human Neuregulin1‐β1 Significantly Reduces Schwannoma Growth in Mice 0.75
6 1.32
Robotic Pancreatoduodenectomy Carries Greater Risk of Morbidity after Conversion than Laparoscopy: A Propensity Score-Matched Analysis in the E-MIPS Registry. 0.09
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.17
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.03
Impact of Merging two high-volume Centers on Patient Outcome: 1000 Consecutive Pancreatoduodenectomies. 0.02
Adherence to Multidisciplinary Tumor Board Decisions Determines Long-term Survival in Patients with Hepatocellular Carcinoma. 0.97
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. 0.05
4 3.32
Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series 0.92
Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series 0.93
A germline IκBα mutation outside the signal reception domain blocks nuclear translocation of NFκB1 and associates with autoinflammation-like features 1.00
Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus 0.47
20 7.68
Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis 0.30
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study 0.10
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay 0.91
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia 0.13
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability 0.03
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.15
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia 0.88
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma 0.13
CPX-351 in Down syndrome–associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial 0.77
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial 1.00
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma 1.00
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.06
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.05
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.04
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin 0.02
CircFUT8 promotes proplatelet formation by interacting with IGF2BP2 and stabilizing TNS1 mRNA in megakaryocytes 0.08
Clinical presentation, management and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy 0.10
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens 0.91
Iron overload in HFE-related hemochromatosis severely impairs Vδ2+ γδ T-cell homeostasis 1.00
4 0.57
Surgical Outcomes from Nationwide Implementation of the International Best-Practice for Locally Advanced Pancreatic Cancer (PREOPANC-4) study 0.03
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.05
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma 0.05
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study 0.45
6 1.07
Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma 0.07
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration 0.05
A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies 0.06
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma 0.83
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition 0.02
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture 0.04
7 3.27
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma 0.13
Integrated Single-Nucleus and Spatial Transcriptomics Elucidate Heterogeneity and Hypoxia-Driven Organization of Supratentorial Ependymoma. 1.00
PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth. 0.10
FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia. 1.00
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer 0.02
Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors 1.00
Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression 0.03
7 2.08
Rational discovery of therapeutic PAK1 allosteric activators 0.05
The E3-ome gene-centric compendium reveals the human E3 ligase landscape 0.12
Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial 0.04
MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids 0.90
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis 0.06
A split-site E3 ligase mechanism enables ZNFX1 to ubiquitinate and cluster single-stranded RNA into ubiquitin-coated nucleoprotein particles 0.17
Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia 0.74
2 0.65
Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across age groups and sequencing methods 0.63
Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer 0.03
1 0.02
Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer 0.02
2 0.93
ZNF512B safeguards genome integrity at regulatory regions to repress the SASP and inflammation 0.05
Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML 0.88
2 1.57
Histidine methylation via an enzymatic cascade with in situ generation of nucleoside-modified AdoMet analogues 0.57
Red-light excitation of a Ru(ii)–Pt(ii) tetranuclear complex for combined photoactivated chemotherapy and photodynamic therapy 1.00
1 0.19
Light-triggered toll-like receptor activation in a nanoscale metal–organic framework for synergistic PDT and cancer immunotherapy 0.19
3 1.06
Targeting Interleukin-8-Mediated Cellular Crosstalk Reverses Hypertrophic Cardiomyopathy and Cardiac Fibrosis in Noonan Syndrome. 0.98
Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension 0.03
miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. 0.06
3 1.64
Cohesin and its regulation promote monopolar kinetochore orientation at meiosis I in Arabidopsis 0.50
Extracellular matrix restrains cell-cycle progression by nuclear exclusion of Yorkie in Drosophila 1.00
Polo kinase inhibits protein phosphatase 1 to promote the spindle assembly checkpoint and prevent aneuploidy 0.14
3 1.07
Multi-omic analyses reveal a differential contribution of chromatin-associated PP1 holoenzymes to mitotic exit and G1 re-establishment 0.06
Maternal CENP-C restores centromere symmetry in mammalian zygotes to ensure proper chromosome segregation 0.05
Rbpms2 prevents major cardiac defects in cardiomyocyte-specific Rbpms-deficient mice 0.96
5 1.68
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry 0.59
Histopathology-based Artificial Intelligence Algorithms for the Prediction of Prostate Cancer Metastasis After Radical Prostatectomy 0.02
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial 0.03
Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial 0.65
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma 0.38
3 1.96
Mutational Landscape of Colorectal Tumors From Individuals With Unexplained Adenomatous or Serrated Colorectal Polyposis 0.44
Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 0.52
Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer 1.00
7 1.54
Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism 0.13
Molecular and cellular consequences of tumour-autonomous IL-6 signalling in intrahepatic cholangiocarcinoma 0.08
Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis 0.97
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.10
Comparative risk of high-risk neoplasia after polypectomy among individuals aged below 50 years versus 50 years and older 0.11
Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial 0.13
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential 0.03
4 0.56
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.07
Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma. 0.04
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway. 0.03
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma. 0.41
2 1.03
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.03
Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells 1.00
2 1.07
Macropa Scaffold Expansion for Actinium-225 Chelation: A Synthetic Strategy, Labeling Kinetics, and Theoretical Calculations 0.82
Heavy Alkaline Earth Radiometals for Cancer Theranostics: Coordination and Radiochemistry of Radium-223 and Barium-131 with Kryptofix 22-Based Chelators 0.25
3 0.54
Investigating the association between anthropometry and colorectal cancer survival: a two-sample Mendelian randomization analysis 0.06
Geographic analysis and trends in mortality from mesothelioma in Mexico 1998–2022 0.44
Maternal prenatal infection and childhood leukaemia: a Childhood Cancer and Leukemia International Consortium (CLIC) meta-analysis 0.03
3 0.18
Activity and Physiological Stress Within 90 Days After Minimally Invasive and Open Pancreatoduodenectomy: A Predefined Analysis of the DIPLOMA-2 Randomized Clinical Trial. 0.03
International Reference Values for Surgical Outcomes of Total Pancreatectomy 0.08
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer 0.07
1 0.10
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis 0.10
10 7.04
Splicing dependency between EIF4G2 introns is mediated by exon definition and relies on a downstream splicing event 0.33
An isotype-specific phosphorylation of Hsp90 rewires co-chaperone regulations 0.60
Exploring the organismal role of UFMylation in development, stress resilience, and neurological function in Caenorhabditis elegans 0.86
Genome-wide chromatin profiling reveals a nonlimiting role for RXR in macrophage-like cells stimulated with multiple nuclear receptor agonists 0.09
HSP-1-Specific Nanobodies Alter Chaperone Function in vitro and in vivo 0.15
Minimal Actin Cortices: The αD-Helix of Ezrin’s C-ERMAD Governs F-Actin Binding 1.00
SDF2 and SDF2L1 are essential co-factors of DNAJB11 for Polycystin-1 processing 1.00
The E3 ubiquitin ligase SPRYD3-MYCBP2(PAM) regulates mitotic cell fate and ubiquitination of USP11 to control spindle assembly 1.00
The activity of the EMT suppressor GRHL2 is regulated by SUMOylation 1.00
Conformations of the three gates in Saccharomyces cerevisiae topoisomerase II and their response to DNA, nucleotide, and etoposide 1.00
2 1.07
Phosphoproteomic identification of Mos–MAPK targets in meiotic cell cycle and asymmetric oocyte divisions 1.00
Moesin controls cell–cell fusion and osteoclast function 0.07
4 3.05
Outcome of first-line chemotherapy for anaplastic thyroid cancer—a multicenter registry analysis 1.00
An Interpretable Machine Learning Model for Predicting Occult Central Lymph Node Metastasis in Papillary Thyroid Cancer 0.05
Delineating Pediatric Adrenocortical Tumors by GC-MS Urinary Steroid Metabolome Analysis: Observations From the MET Study 1.00
Machine Learning Prediction of Recurrence in Pediatric Thyroid Cancer: Malignant Endocrine Tumors Cohort Analysis Using XGBoost and SHAP 1.00
11 3.71
Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model 0.69
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma 0.63
Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization 0.94
Rho/ROCK signaling and α-Catenin mediate β-Catenin-driven hyperplasia in the adrenal cortex via adherens junctions 0.04
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma 0.93
Acetyl-CoA carboxylase-1 inhibition increases regulatory T-Cell metabolism and graft-vs-host disease treatment efficacy via mitochondrial fusion 0.09
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose 0.04
USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer 0.19
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia 0.03
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models 0.10
Mutations in spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly 0.04
31 7.66
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial 0.04
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.03
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.04
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). 0.05
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. 0.92
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. 0.09
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. 0.34
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer. 0.02
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II). 0.25
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study. 0.45
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.04
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.05
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.05
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. 0.39
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.03
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. 0.03
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer. 0.91
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009. 0.33
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report. 0.04
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. 0.07
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.03
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. 0.09
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.10
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. 0.71
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. 0.35
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. 1.00
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.09
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 0.33
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.06
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. 0.71
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). 0.03
4 2.01
NIK-driven IL-23 production by myeloid cells is a key factor in the development of autoimmune inflammation 0.75
Liver-X-receptor agonism enhances T cell priming and activation to promote anti-tumor immunity 0.24
Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function 0.02
RIPK1 autophosphorylation at S161 mediates cell death and inflammation 1.00
3 0.23
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma 0.07
Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression 0.04
Detection of esophageal varices and prediction of hepatic decompensation in unresectable hepatocellular carcinoma using AI 0.12
2 0.65
Validation of PARACELSUS score performance for the diagnosis of pyoderma gangrenosum: An international multicenter study with 1403 cases 0.45
Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study 0.20
3 1.05
MSA-2 Loaded Three-Dimensional Metal Covalent Organic Framework for Synergistic Radiosensitization and Innate Immune Activation 0.04
Autonomous Activation of a Gated Chemiluminescent Photosensitizer Enables Targeted Photodynamic Therapy in Tumor Cells 0.94
Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer 0.07
18 3.15
Temporal Trends of Subsequent Malignant Neoplasms in Childhood Cancer Survivors and the Impact of Treatment Changes: A DCCSS-LATER Study 0.03
Change in body mass index and physical activity and postmenopausal breast cancer risk in a cohort of Dutch nurses 0.11
<atl>Toxicity-over-time analysis of anti-EGFR-based maintenance versus stopamp;go in left-sided, iRAS/BRAF/i wild-type metastatic colorectal cancer</atl> 0.21
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25) 0.12
Premenopausal and postmenopausal obesity and endometrial cancer risk: circulating biomarkers of inflammation, insulin resistance, and sex hormones as mediators 0.08
Risk of Subsequent Primary Melanoma in 68,002 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup cohort study 0.08
Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer 0.93
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials 0.05
A smoking-related plasma protein score and smoking-related cancer risk and mortality in ARIC 0.02
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer 0.21
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.03
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials 0.07
Early-detection and prevention effects of screening sigmoidoscopy: evidence from randomized trials revisited 1.00
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.01
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.03
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma 0.01
Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer 0.11
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.07
1 0.13
A predictor finding study found patient-reported outcomes improve the prediction of mortality of incident dialysis patients 0.13
8 5.36
A time-resolved atlas of histone modifications during mitotic entry 0.23
RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response 0.63
The essential co-chaperone Sgt1 regulates client dwell time in the Hsp90 chaperone cycle 0.82
A Leishmania virulence factor harnesses an allosteric kinase switch to regulate its ubiquitin ligase activity 0.88
Ubiquitin precursor with C-terminal extension promotes proteostasis and longevity 1.00
Rapid UPF1 depletion illuminates the temporal dynamics of the NMD-regulated human transcriptome 1.00
A redox switch in p21-CDK feedback during G2 phase controls the proliferation-cell cycle exit decision 0.45
Condensin II activation by M18BP1 0.35
1 0.10
Chemical vs Physical Radioenhancement from TiO2 and Au Nanoparticles to Overcome Hypoxic Radioresistance in X-ray Therapy 0.10
20 6.03
Centromeric footprints preserve telomere integrity in ALT cancers 0.10
Acquired genetic and cell-state changes in IDH-mutant glioma progression 0.01
Evolutionary characterization of lung cancer metastasis 0.00
Thymic health and immunotherapy outcomes in patients with cancer 0.01
Ageing promotes metastasis via activation of the integrated stress response 0.02
Multidimensional profiling of heterogeneity in supratentorial ependymomas 0.27
Precancerous niche remodelling dictates nascent tumour persistence 0.24
Ancient co-option of LTR retrotransposons as yeast centromeres 0.25
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC 0.95
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance 0.71
Progressive coevolution of the yeast centromere and kinetochore 0.63
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance 0.02
Genetic elements promote retention of extrachromosomal DNA in cancer cells 0.06
Lymph node environment drives FSP1 targetability in metastasizing melanoma 0.25
Targeting FSP1 triggers ferroptosis in lung cancer 0.10
Origins of chromosome instability unveiled by coupled imaging and genomics 0.89
Functional synapses between neurons and small cell lung cancer 0.92
A missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia 0.49
NASP modulates histone turnover to drive PARP inhibitor resistance 0.07
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity 0.04
1 0.04
Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors 0.04
2 1.10
Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability 0.15
Fructose-1,6-bisphosphate couples glycolytic activity to cell adhesion 0.95
1 0.13
Drug-controlled CAR T cells through the regulation of cell–cell interactions 0.13
91 40.70
Glioma-intrinsic MAPK/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses 0.14
POLY-Senolytic nanoplatform for tumor-specific eradication of senescent tumor cells and mitigation of radiotherapy-induced immune resistance of cancer 0.08
Reverse engineering of BNIP3 identifies a mitochondrial protective peptide 1.00
Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis 0.85
Systematic discovery of UFM1 receptors reveals a regulatory module in DNA repair directing non-homologous end-joining 0.15
Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancer 0.17
Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies 0.05
RBM20 isoform regulation by independent transcription start sites adapts alternative splicing in development and disease 0.86
Tumor sialylation regulates G-CSF stability and promotes neutrophil-mediated immunosuppression in breast cancer 0.13
GPCR kinases shape ACKR4 functions via differential C-terminal phosphorylation 0.05
Variant U1 snRNAs contribute to cell cycle and differentiation control of human iPS cells 1.00
Molecular anatomy of PLK1 master docking motifs 1.00
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial 0.07
Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy 0.04
Correction of the molecular phenotype of X-linked Dystonia-Parkinsonism reveals a non-canonical function of BRD4 0.80
Activating p53Y220C with a mutant-specific small molecule 0.16
Reprogramming of bacterial virulence by lysine acetylation 1.00
2′--methylation-dependent installation of -methylguanosine in the U6 internal stem loop facilitates efficient spliceosome assembly 0.81
Single cell transcriptional evolution of myeloid leukemia of Down syndrome 0.16
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients 0.18
Recurrent DNA break clusters drive replication-stress-induced copy number variants and genome diversification 1.00
Discovery of an Endonuclease G-inhibitory Ku80-peptide protecting against leukemogenic rearrangements at the MLL breakpoint cluster 1.00
Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer 0.31
Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy 0.96
Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination 0.80
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor 0.92
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial 0.84
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.14
HR3/RORα-mediated cholesterol sensing regulates TOR signaling 0.06
Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcoma 0.08
Phosphorylation of SF3B1 by CDK11 orchestrates spliceosome activation via SNIP1-dependent RES complex recruitment 0.07
Iminium-linked hyperporphyrin covalent organic framework mediates type I photodynamic therapy via a photoredox process 0.05
Maturase K forms a plastidial splicing complex with a neofunctionalized branching enzyme 0.18
Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target 0.89
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial 1.00
NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors 0.06
Composite SMG5-SMG6 PIN domain formation is essential for NMD 1.00
HIF sustain a transcriptional regulatory circuit of EPAS1 expression in renal clear cell carcinoma 0.92
Phytic acid (InsP6) activates HDAC3 epigenetic axis to maintain intestinal barrier function 0.13
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma 0.90
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy 0.03
Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression 0.04
Modulation of Nudt21 levels reveals dose-dependent roles of alternative polyadenylation in tissue regeneration 0.25
De novo variants in the splicing factor gene are associated with neurodevelopmental disorders 0.03
Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy 0.07
Mechanistic insights into recruitment and regulation of the RNA helicase UPF1 in replication-dependent histone mRNA decay 0.88
WRN structural flexibility showcased through fragment-based lead discovery of inhibitors 0.08
Multi-scale classification decodes the complexity of the human E3 ligome 0.98
Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer 0.44
Kinetochore mutations and histone phosphorylation pattern changes accompany holo- and macro-monocentromere evolution 0.81
Reconstructing the three-dimensional architecture of extrachromosomal DNA with ec3D 0.09
Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression 1.00
LncRNA regulates cell size in human and mouse by guiding FOSL2 0.03
G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patients 1.00
Fragment-based discovery enables direct targeting of the melanoma oncogene MITF 0.03
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.06
A JAK/STAT-Pdk1-S6K axis bypasses systemic growth restrictions to promote regeneration 1.00
Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation 0.76
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations 0.05
Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies 0.15
MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis 0.53
Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis 0.09
An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome 0.11
Bidirectional communication between nucleotide and substrate binding sites in a type IV multidrug ABC transporter 0.44
LUBAC modulates CBM complex functions downstream of TRAF6 in T cells 0.94
Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma 0.04
Astrocytic-OTUD7B ameliorates murine experimental autoimmune encephalomyelitis by stabilizing glial fibrillary acidic protein and preventing inflammation 0.96
The Hippo terminal effector YAP boosts enterovirus replication in type 1 diabetes 0.74
Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry 0.07
Stabilizing a mammalian RNA thermometer confers neuroprotection in subarachnoid hemorrhage 0.28
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity 0.03
Selective ubiquitination of drug-like small molecules by the ubiquitin ligase HUWE1 1.00
Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing 0.04
Structural basis of adhesin Fap2 interaction with receptors on cancer and immune cells 1.00
Hepatitis C virus NS3 helicase contributes to (−) strand RNA synthesis 0.60
ALS/FTD-linked TBK1 deficiency in microglia induces an aged-like microglial signature and drives social recognition deficits in mice 0.09
The bispecific innate cell engager AFM28 eliminates CD123 leukemic stem and progenitor cells in AML and MDS 1.00
Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition 0.04
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target 0.12
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma 0.03
Bioinspired ruthenium-manganese-oxygen complex for biocatalytic and radiosensitization therapies to eradicate primary and metastatic tumors 0.08
Chromatin retained lncRNA integrates ABA and DOG1 signalling pathways to enhance Arabidopsis seeds dormancy 0.08
Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression 0.92
Pre-mRNA processing factors differentially impact coordination between co-transcriptional cleavage and transcription termination 0.06
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas 0.11
Structure and mechanism of the RalGAP tumor suppressor complex 1.00
Allosteric activation of the SPRTN protease by ubiquitin maintains genome stability 0.89
Notch activity is modulated by the aGPCR Latrophilin binding the DSL ligand in C. elegans 0.88
Interdependence of Pasha and Drosha for localization and function of the Microprocessor in C. elegans 0.17
Structure of a transcribing Pol II-DSIF-SPT6-U1 snRNP complex 0.56
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial 0.02
14 2.18
High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia 0.09
Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes 0.16
Systematic analysis of snRNA genes reveals frequent variants in dominant and recessive developmental and epileptic encephalopathies 0.13
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.05
CDK4/6 inhibition mitigates chemotherapy-induced expansion of -mutant clonal hematopoiesis 0.03
Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types 0.13
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.04
Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma 0.09
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations 0.80
Transcription factor switching drives subtype-specific pancreatic cancer 0.19
Rapid epigenomic classification of acute leukemia 0.09
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis 0.02
Tamoxifen induces PI3K activation in uterine cancer 0.01
Temporal genomic dynamics shape clinical trajectory in multiple myeloma 0.34
1 0.58
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma 0.58
3 0.34
Fibronectin matrix remodelling modulates the active nematic dynamics of cancer-associated fibroblasts 0.07
Restoring the tumour mechanophenotype of vocal fold cancer reverts its malignant properties 0.04
Cell viscosity influences haematogenous dissemination and metastatic extravasation of tumour cells 0.23
24 7.31
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 0.84
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 1.00
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial 0.07
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial 0.08
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.17
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial 0.02
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases 1.00
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases 0.27
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.08
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.01
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial 0.00
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma 0.29
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma 0.02
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial 0.86
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial 0.89
Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life 0.11
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.04
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.05
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial 1.00
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial 0.06
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.06
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial 0.04
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.31
1 0.04
Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape 0.04
2 1.17
UBA6 specificity for ubiquitin E2 conjugating enzymes reveals a priority mechanism of BIRC6 0.17
Conformational plasticity of a BiP–GRP94 chaperone complex 1.00
1 1.00
Inducible gene deletion reveals essentiality of protein kinases and a septation initiation network in Candida albicans 1.00
1 0.10
Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study. 0.10
15 6.53
APOBEC2 deficiency disrupts hematopoietic lineage commitment, resulting in emergence of dual identity lymphocytes in mice and humans 0.61
In vivo binding by Arabidopsis SPLICING FACTOR 1 shifts 3′ splice-site choice, regulating circadian rhythms and immunity in plants 0.32
DARPins as pan-reactivators of temperature-sensitive p53 cancer mutants 0.81
mtHsp70 chaperone converts mitochondrial proteostasis stress into impaired protein import 1.00
Microglial fructose metabolism is essential for glioblastoma growth 0.03
E2 variants for probing E3 ubiquitin ligase activities 0.80
Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition 0.40
Control of renal calcium permeability via a tight junctional claudin switch 0.83
The liver talks back: NPY orchestrates attraction of cancer cells and CHK2-dependent clonogenicity in the metastatic niche 0.87
Citrullination negatively regulates the functions of the p53 protein and opposes its ubiquitination and degradation 0.09
Functional spectrum of USP7 pathogenic variants in Hao–Fountain syndrome: Insights into the enzyme’s activity, stability, and allosteric modulation 0.18
The activity and expression of adenylosuccinate lyase were reduced during modern human evolution, affecting brain and behavior 0.15
Neutron and time-resolved X-ray crystallography reveal the substrate recognition and catalytic mechanism of human Nudix hydrolase MTH1 0.18
Inactivation of PI3K-C2α deregulates cell death pathways and sensitizes to endotoxic shock 0.20
The WWP1–JARID1B axis sustains acute myeloid leukemia chemoresistance 0.05
3 2.20
Transarterial Radioembolization: Medical Staff Dosimetry for 90Y-Resin, 90Y-Glass, and 166Ho-PLLA Microspheres. 1.00
False-Positive Recall and False-Positive Biopsy Rates in Mammography Screening: A TOSYMA Trial Subanalysis. 1.00
Cancer Detection in Breast MRI Screening via Explainable AI Anomaly Detection. 0.20
3 0.20
Lymphoid tissue chemokines limit priming duration to preserve CD8+ T cell functionality 0.06
Mechanisms linking cytoplasmic decay of translation-defective mRNA to transcriptional adaptation 0.06
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation 0.08
11 6.07
SIRT2 antagonizes MOF function during mitotic entry 0.05
Regulation of NAT1 activity in modern humans by a novel phosphorylation site 0.78
KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival 0.79
The accessory adapters FAF1, FAF2, and UBXN7 accelerate proteasomal degradation by increasing prior p97-mediated substrate unfolding 1.00
Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression 0.63
Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment 0.01
The BUB1 and BUBR1 paralogs scaffold the kinetochore fibrous corona 1.00
Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma 0.71
M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development 0.07
Plant defense-directed discovery of a natural anti-psoriasis agent targeting GAPDH 0.10
TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer 0.93
6 1.84
Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction 0.13
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models 0.10
Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat 0.99
Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice 0.52
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer 0.03
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer 0.07
11 4.63
Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer 0.95
Microtubule end stabilisation by cooperative oligomers of Ska and Ndc80 complexes 0.08
M18BP1 valency and a distributed interaction footprint determine epigenetic centromere specification in humans 1.00
Homeostatic control of energy metabolism by monocyte-derived macrophages 0.05
The transaminase-ω-amidase pathway senses oxidative stress to control glutamine metabolism and α-ketoglutarate levels in endothelial cells 0.89
Concurrence of mutations modulates oncogenesis in glioneuronal tumors 0.05
Nucleosome interaction of the CPC secures centromeric chromatin integrity and chromosome segregation fidelity 0.27
Functional landscape of ubiquitin linkages couples K29-linked ubiquitylation to epigenome integrity 0.25
TXNIP mediates LAT1/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence 0.02
Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer 0.06
mTORC1 senses glutamine and other amino acids through GCN2. 1.00
1 0.25
Purinosome Unmasked: Exploring the Molecular-Scale Structure of a Purinosome Complex In Silico 0.25
9 0.44
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial 0.06
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study 0.03
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.03
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.05
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial 0.05
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.06
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.05
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
22 3.84
Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials 0.50
[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study 0.05
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study 0.08
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial 0.10
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.06
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.05
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.10
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.07
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial 0.10
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials 0.72
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.01
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group 0.26
Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study 0.07
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study 1.00
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial 0.05
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.04
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study 0.18
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis 0.16
Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study 0.10
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.05
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.05
18 1.20
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma 0.03
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer 0.05
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer 0.05
Perioperative Apalutamide in High-Risk Localized Prostate Cancer 0.09
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer 0.11
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.04
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.21
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer 0.09
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.12
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer 0.05
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.07
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.05
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.10
European Study of Prostate Cancer Screening — 23-Year Follow-up 0.01
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.03
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.06
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.02
1 0.61
Ubiquitin-dependent proteolysis of KNL2 driven by APC/CCDC20 is critical for centromere integrity and mitotic fidelity 0.61
1 0.43
Increase in second primary lung cancers in a nation-wide cohort study from Sweden 0.43

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.